Full Press Release Details
Non-GAAP Financial Measures Included in the Financial Tables
These revenue schedules include adjusted revenues and revenue growth rates on a currency-neutral, adjusted and organic basis. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States. BD management believes that the use of non-GAAP measures to adjust for items that are considered by management to be outside of BD's underlying operational results or that affect period-to-period comparability helps investors to gain a better understanding of our performance year-over-year, to analyze underlying trends in our businesses, to analyze our operating results and to understand future prospects. Management uses these non-GAAP financial measures to measure and forecast the Company's performance, especially when comparing such results to prior periods or forecasts. We believe presenting such measures provides investors with greater transparency to the information used by BD management for its operational decision-making and for comparison to other companies within the medical technology industry. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. BD strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP measures used by BD may differ from similar measures used by other companies, even when similar terms are used to identify such measures. Non-GAAP measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
We present revenue growth rates as compared to the corresponding prior periods on a currency-neutral basis after eliminating the effect of foreign currency translation, where applicable. We calculate foreign currency-neutral percentages by converting the current-period local currency financial results using the corresponding prior period foreign currency exchange rates and comparing these adjusted amounts to our current-period results. As exchange rates are an important factor in understanding period-to-period comparisons, we believe the presentation of revenues on a foreign currency-neutral basis in addition to reported results helps improve investors' ability to understand our operating results and evaluate our performance in comparison to prior periods.
We present adjusted revenues for the full fiscal year 2024 and the third quarter of fiscal year 2024, excluding the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, all of which substantially relate to years prior to fiscal year 2024, because we believe these items affect the comparability of the periods presented.
New BD refers to BD post the separation of the Biosciences and Diagnostic Solutions business from BD.
Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUE BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited, $ in millions)
| United States | International | Total | |||||||||||||||||||||||||||||||||||||||||||||
| % Change | % Change | ||||||||||||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | FX Impact | Reported | FXN | 2025 | 2024 | FX Impact | Reported | FXN | |||||||||||||||||||||||||||||||||||
| Medical Essentials (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Delivery Solutions | $ | 2,789 | $ | 2,661 | 4.8 | $ | 1,787 | $ | 1,768 | $ | (7) | 1.0 | 1.4 | $ | 4,575 | $ | 4,429 | $ | (7) | 3.3 | 3.5 | ||||||||||||||||||||||||||
| Specimen Management | 981 | 952 | 3.0 | 890 | 882 | (2) | 0.9 | 1.1 | 1,871 | 1,833 | (2) | 2.0 | 2.1 | ||||||||||||||||||||||||||||||||||
| Total | $ | 3,770 | $ | 3,612 | 4.4 | $ | 2,676 | $ | 2,650 | $ | (9) | 1.0 | 1.3 | $ | 6,446 | $ | 6,262 | $ | (9) | 2.9 | 3.1 | ||||||||||||||||||||||||||
| Connected Care (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Management Solutions | $ | 2,810 | $ | 2,627 | 7.0 | $ | 664 | $ | 670 | $ | 5 | (1.0) | (1.7) | $ | 3,474 | $ | 3,297 | $ | 5 | 5.4 | 5.2 | ||||||||||||||||||||||||||
| Advanced Patient Monitoring | 658 | 47 | NM | 424 | 27 | 2 | NM | NM | 1,082 | 74 | 2 | NM | NM | ||||||||||||||||||||||||||||||||||
| Total | $ | 3,469 | $ | 2,674 | 29.7 | $ | 1,088 | $ | 697 | $ | 7 | 56.0 | 55.0 | $ | 4,556 | $ | 3,371 | $ | 7 | 35.2 | 34.9 | ||||||||||||||||||||||||||
| BioPharma Systems (1)(2) | $ | 659 | $ | 629 | 4.7 | $ | 1,666 | $ | 1,644 | $ | 15 | 1.3 | 0.4 | $ | 2,324 | $ | 2,273 | $ | 15 | 2.2 | 1.6 | ||||||||||||||||||||||||||
| Interventional (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Peripheral Intervention | $ | 1,067 | $ | 1,029 | 3.8 | $ | 929 | $ | 904 | $ | 2 | 2.7 | 2.5 | $ | 1,996 | $ | 1,933 | $ | 2 | 3.3 | 3.2 | ||||||||||||||||||||||||||
| Urology and Critical Care | 1,303 | 1,236 | 5.5 | 345 | 319 | 3 | 8.4 | 7.6 | 1,649 | 1,554 | 3 | 6.1 | 5.9 | ||||||||||||||||||||||||||||||||||
| Surgery | 1,175 | 1,130 | 4.0 | 397 | 363 | 2 | 9.5 | 8.9 | 1,572 | 1,492 | 2 | 5.3 | 5.2 | ||||||||||||||||||||||||||||||||||
| Total | $ | 3,545 | $ | 3,394 | 4.5 | $ | 1,671 | $ | 1,586 | $ | 6 | 5.4 | 5.0 | $ | 5,217 | $ | 4,980 | $ | 6 | 4.8 | 4.6 | ||||||||||||||||||||||||||
| Life Sciences (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Diagnostic Solutions | $ | 755 | $ | 782 | (3.4) | $ | 1,083 | $ | 1,064 | $ | 5 | 1.8 | 1.4 | $ | 1,838 | $ | 1,846 | $ | 5 | (0.4) | (0.7) | ||||||||||||||||||||||||||
| Biosciences | 593 | 577 | 2.8 | 865 | 935 | 6 | (7.5) | (8.1) | 1,458 | 1,512 | 6 | (3.6) | (4.0) | ||||||||||||||||||||||||||||||||||
| Total | $ | 1,348 | $ | 1,358 | (0.8) | $ | 1,948 | $ | 1,999 | $ | 11 | (2.6) | (3.1) | $ | 3,296 | $ | 3,358 | $ | 11 | (1.8) | (2.2) | ||||||||||||||||||||||||||
| Other (3) | $ | - | $ | (6) | (100.0) | $ | - | $ | (62) | $ | - | (100.0) | (100.0) | $ | - | $ | (67) | $ | - | (100.0) | (100.0) | ||||||||||||||||||||||||||
| Total Revenues | $ | 12,790 | $ | 11,663 | 9.7 | $ | 9,049 | $ | 8,515 | $ | 30 | 6.3 | 5.9 | $ | 21,840 | $ | 20,178 | $ | 30 | 8.2 | 8.1 |
NM denotes that the percentage change is not meaningful.
(1)Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.
(2)The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.
(3)Represents the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, all of which substantially relate to years prior to fiscal year 2024. Such amounts were not allocated to our reportable segments.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
RECONCILIATION OF REPORTED REVENUE CHANGE TO ADJUSTED REVENUE CHANGE TO NEW BD ADJUSTED REVENUE CHANGE AND ADJUSTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE
Twelve Months Ended September 30,
(Unaudited, $ in millions)
| % Change | ||||||||||||||||||
| 2025 | 2024 | FX Impact | Reported | FXN | ||||||||||||||
| Total Revenues | $ | 21,840 | $ | 20,178 | $ | 30 | 8.2 | 8.1 | ||||||||||
| Add Reduction for government legislative and legal matters (1) | - | 67 | - | (100.0) | (100.0) | |||||||||||||
| Adjusted Total Revenues | $ | 21,840 | $ | 20,245 | $ | 30 | 7.9 | 7.7 | ||||||||||
| Less Life Sciences Segment Revenue | 3,296 | 3,358 | 11 | (1.8) | (2.2) | |||||||||||||
| Total New BD Adjusted Revenue (2) | $ | 18,544 | $ | 16,887 | $ | 19 | 9.8 | 9.7 | ||||||||||
| Adjusted Total Revenues | $ | 21,840 | $ | 20,245 | $ | 30 | 7.9 | 7.7 | ||||||||||
| Less Inorganic revenue adjustment (3) | 977 | - | 1 | NM | NM | |||||||||||||
| Organic Revenue | $ | 20,863 | $ | 20,245 | $ | 28 | 3.1 | 2.9 | ||||||||||
| Less Life Sciences Segment Revenue | 3,296 | 3,358 | 11 | (1.8) | (2.2) | |||||||||||||
| Total New BD Organic Revenue (4) | $ | 17,567 | $ | 16,887 | $ | 18 | 4.0 | 3.9 | ||||||||||
| Connected Care Revenue | $ | 4,556 | $ | 3,371 | $ | 7 | 35.2 | 34.9 | ||||||||||
| Less Inorganic revenue adjustment (3) | 977 | - | 1 | NM | NM | |||||||||||||
| Connected Care Organic Revenue | $ | 3,580 | $ | 3,371 | $ | 6 | 6.2 | 6.0 |
NM denotes that the percentage change is not meaningful.
(1)Represents the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, and which substantially relate to years prior to fiscal year 2024.
(2)Total New BD Adjusted Revenue is inclusive of Adjusted Total Revenues attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
(3)Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition divestiture. Acquisitions include Advanced Patient Monitoring in the Connected Care segment.
(4)Total New BD Organic Revenue is inclusive of Organic Revenue attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUE BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited, $ in millions)
| United States | International | Total | |||||||||||||||||||||||||||||||||||||||||||||
| % Change | % Change | ||||||||||||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | FX Impact | Reported | FXN | 2025 | 2024 | FX Impact | Reported | FXN | |||||||||||||||||||||||||||||||||||
| Medical Essentials (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Delivery Solutions | $ | 728 | $ | 689 | 5.7 | $ | 474 | $ | 458 | $ | 12 | 3.5 | 0.9 | $ | 1,202 | $ | 1,147 | $ | 12 | 4.8 | 3.8 | ||||||||||||||||||||||||||
| Specimen Management | 260 | 244 | 6.6 | 223 | 218 | 7 | 2.6 | (0.5) | 483 | 462 | 7 | 4.7 | 3.3 | ||||||||||||||||||||||||||||||||||
| Total | $ | 988 | $ | 933 | 5.9 | $ | 697 | $ | 676 | $ | 19 | 3.2 | 0.4 | $ | 1,686 | $ | 1,609 | $ | 19 | 4.8 | 3.6 | ||||||||||||||||||||||||||
| Connected Care (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Management Solutions | $ | 780 | $ | 744 | 4.9 | $ | 194 | $ | 195 | $ | 6 | (0.4) | (3.8) | $ | 974 | $ | 939 | $ | 6 | 3.8 | 3.1 | ||||||||||||||||||||||||||
| Advanced Patient Monitoring | 169 | 47 | NM | 107 | 27 | 3 | NM | NM | 276 | 74 | 3 | NM | NM | ||||||||||||||||||||||||||||||||||
| Total | $ | 949 | $ | 791 | 20.0 | $ | 301 | $ | 222 | $ | 10 | 35.7 | 31.3 | $ | 1,250 | $ | 1,013 | $ | 10 | 23.4 | 22.5 | ||||||||||||||||||||||||||
| BioPharma Systems (1)(2) | $ | 228 | $ | 187 | 21.5 | $ | 475 | $ | 490 | $ | 16 | (3.1) | (6.3) | $ | 702 | $ | 677 | $ | 16 | 3.7 | 1.4 | ||||||||||||||||||||||||||
| Interventional (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Peripheral Intervention | $ | 275 | $ | 267 | 2.9 | $ | 256 | $ | 235 | $ | 7 | 8.7 | 5.8 | $ | 530 | $ | 502 | $ | 7 | 5.6 | 4.3 | ||||||||||||||||||||||||||
| Urology and Critical Care | 341 | 306 | 11.6 | 97 | 84 | 3 | 14.7 | 11.1 | 437 | 390 | 3 | 12.2 | 11.5 | ||||||||||||||||||||||||||||||||||
| Surgery | 290 | 279 | 4.0 | 110 | 89 | 3 | 22.6 | 18.9 | 400 | 368 | 3 | 8.5 | 7.6 | ||||||||||||||||||||||||||||||||||
| Total | $ | 905 | $ | 851 | 6.4 | $ | 462 | $ | 409 | $ | 13 | 13.0 | 9.8 | $ | 1,367 | $ | 1,260 | $ | 13 | 8.5 | 7.5 | ||||||||||||||||||||||||||
| Life Sciences (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Diagnostic Solutions | $ | 199 | $ | 204 | (2.6) | $ | 300 | $ | 277 | $ | 10 | 8.2 | 4.5 | $ | 498 | $ | 481 | $ | 10 | 3.6 | 1.5 | ||||||||||||||||||||||||||
| Biosciences | 153 | 151 | 1.5 | 234 | 247 | 8 | (5.2) | (8.3) | 387 | 397 | 8 | (2.7) | (4.6) | ||||||||||||||||||||||||||||||||||
| Total | $ | 351 | $ | 354 | (0.8) | $ | 534 | $ | 524 | $ | 18 | 1.9 | (1.5) | $ | 885 | $ | 878 | $ | 18 | 0.8 | (1.2) | ||||||||||||||||||||||||||
| Total Revenues | $ | 3,422 | $ | 3,117 | 9.8 | $ | 2,468 | $ | 2,320 | $ | 75 | 6.4 | 3.2 | $ | 5,890 | $ | 5,437 | $ | 75 | 8.3 | 7.0 |
NM denotes that the percentage change is not meaningful.
(1)Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.
(2)The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
RECONCILIATION OF REPORTED REVENUE CHANGE TO NEW BD REVENUE CHANGE AND REPORTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE
Three Months Ended September 30,
(Unaudited, $ in millions)
| % Change | |||||||||||||||||||
| 2025 | 2024 | FX Impact | Reported | FXN | |||||||||||||||
| Total Revenues | $ | 5,890 | $ | 5,437 | $ | 75 | 8.3 | 7.0 | |||||||||||
| Less Life Sciences Segment Revenue | 885 | 878 | 18 | 0.8 | (1.2) | ||||||||||||||
| Total New BD Revenue (1) | $ | 5,005 | $ | 4,559 | $ | 57 | 9.8 | 8.5 | |||||||||||
| Total Revenues | $ | 5,890 | $ | 5,437 | $ | 75 | 8.3 | 7.0 | |||||||||||
| Less Inorganic revenue adjustment (2) | 170 | - | 3 | NM | NM | ||||||||||||||
| Organic Revenue | $ | 5,720 | $ | 5,437 | $ | 72 | 5.2 | 3.9 | |||||||||||
| Less Life Sciences Segment Revenue | 885 | 878 | 18 | 0.8 | (1.2) | ||||||||||||||
| Total New BD Organic Revenue (3) | $ | 4,835 | $ | 4,559 | $ | 54 | 6.1 | 4.9 | |||||||||||
| Connected Care Revenue | $ | 1,250 | $ | 1,013 | $ | 10 | 23.4 | 22.5 | |||||||||||
| Less Inorganic revenue adjustment (2) | 170 | - | 3 | NM | NM | ||||||||||||||
| Connected Care Organic Revenue | $ | 1,079 | $ | 1,013 | $ | 7 | 6.6 | 5.9 |
NM denotes that the percentage change is not meaningful.
(1)Total New BD Revenue is inclusive of Total Revenues attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
(2)Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition divestiture. Acquisitions include Advanced Patient Monitoring in the Connected Care segment.
(3)Total New BD Organic Revenue is inclusive of Organic Revenue attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUE BY BUSINESS SEGMENTS AND UNITS
Three Months Ended June 30,
(Unaudited, $ in millions)
| United States | International | Total | |||||||||||||||||||||||||||||||||||||||||||||
| % Change | % Change | ||||||||||||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | FX Impact | Reported | FXN | 2025 | 2024 | FX Impact | Reported | FXN | |||||||||||||||||||||||||||||||||||
| Medical Essentials (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Delivery Solutions | $ | 680 | $ | 670 | 1.4 | $ | 452 | $ | 453 | $ | 1 | (0.1) | (0.3) | $ | 1,132 | $ | 1,123 | $ | 1 | 0.8 | 0.7 | ||||||||||||||||||||||||||
| Specimen Management | 240 | 239 | 0.8 | 230 | 228 | 1 | 0.7 | 0.3 | 470 | 467 | 1 | 0.7 | 0.6 | ||||||||||||||||||||||||||||||||||
| Total | $ | 920 | $ | 909 | 1.3 | $ | 682 | $ | 681 | $ | 1 | 0.1 | (0.1) | $ | 1,602 | $ | 1,590 | $ | 1 | 0.8 | 0.7 | ||||||||||||||||||||||||||
| Connected Care (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Management Solutions | $ | 709 | $ | 680 | 4.3 | $ | 179 | $ | 160 | $ | 3 | 11.4 | 9.6 | $ | 888 | $ | 840 | $ | 3 | 5.7 | 5.3 | ||||||||||||||||||||||||||
| Advanced Patient Monitoring | 176 | - | NM | 102 | - | 2 | NM | NM | 278 | - | 2 | NM | NM | ||||||||||||||||||||||||||||||||||
| Total | $ | 885 | $ | 680 | 30.2 | $ | 281 | $ | 160 | $ | 5 | 75.1 | 72.1 | $ | 1,166 | $ | 840 | $ | 5 | 38.8 | 38.2 | ||||||||||||||||||||||||||
| BioPharma Systems (1)(2) | $ | 178 | $ | 158 | 13.2 | $ | 451 | $ | 437 | $ | 6 | 3.1 | 1.7 | $ | 629 | $ | 594 | $ | 6 | 5.8 | 4.8 | ||||||||||||||||||||||||||
| Interventional (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Peripheral Intervention | $ | 271 | $ | 263 | 2.9 | $ | 241 | $ | 225 | $ | 1 | 7.0 | 6.4 | $ | 512 | $ | 488 | $ | 1 | 4.8 | 4.5 | ||||||||||||||||||||||||||
| Urology and Critical Care | 334 | 297 | 12.4 | 88 | 78 | 2 | 12.7 | 10.8 | 422 | 375 | 2 | 12.5 | 12.1 | ||||||||||||||||||||||||||||||||||
| Surgery | 294 | 283 | 3.6 | 101 | 93 | 1 | 9.0 | 7.7 | 395 | 376 | 1 | 4.9 | 4.6 | ||||||||||||||||||||||||||||||||||
| Total | $ | 898 | $ | 844 | 6.5 | $ | 430 | $ | 396 | $ | 4 | 8.6 | 7.6 | $ | 1,328 | $ | 1,240 | $ | 4 | 7.2 | 6.8 | ||||||||||||||||||||||||||
| Life Sciences (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Diagnostic Solutions | $ | 154 | $ | 167 | (7.4) | $ | 271 | $ | 263 | $ | 3 | 3.1 | 1.8 | $ | 425 | $ | 429 | $ | 3 | (1.0) | (1.8) | ||||||||||||||||||||||||||
| Biosciences | 145 | 141 | 2.9 | 213 | 222 | 3 | (4.1) | (5.6) | 358 | 363 | 3 | (1.3) | (2.3) | ||||||||||||||||||||||||||||||||||
| Total | $ | 299 | $ | 307 | (2.6) | $ | 484 | $ | 485 | $ | 7 | (0.2) | (1.6) | $ | 784 | $ | 793 | $ | 7 | (1.1) | (2.0) | ||||||||||||||||||||||||||
| Other (3) | $ | - | $ | (6) | (100.0) | $ | - | $ | (62) | $ | - | (100.0) | (100.0) | $ | - | $ | (67) | $ | - | (100.0) | (100.0) | ||||||||||||||||||||||||||
| Total Revenues | $ | 3,181 | $ | 2,891 | 10.0 | $ | 2,328 | $ | 2,098 | $ | 23 | 11.0 | 9.8 | $ | 5,509 | $ | 4,990 | $ | 23 | 10.4 | 9.9 |
NM denotes that the percentage change is not meaningful.
(1)Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.
(2)The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.
(3)Represents the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, all of which substantially relate to years prior to fiscal year 2024. Such amounts were not allocated to our reportable segments.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
RECONCILIATION OF REPORTED REVENUE CHANGE TO ADJUSTED REVENUE CHANGE TO NEW BD ADJUSTED REVENUE CHANGE AND ADJUSTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE
Three Months Ended June 30,
(Unaudited, $ in millions)
| % Change | ||||||||||||||||||
| 2025 | 2024 | FX Impact | Reported | FXN | ||||||||||||||
| Total Revenues | $ | 5,509 | $ | 4,990 | $ | 23 | 10.4 | 9.9 | ||||||||||
| Add Reduction for government legislative and legal matters (1) | - | 67 | - | (100.0) | (100.0) | |||||||||||||
| Adjusted Total Revenues | $ | 5,509 | $ | 5,057 | $ | 23 | 8.9 | 8.5 | ||||||||||
| Less Life Sciences Segment Revenue | 784 | 793 | 7 | (1.1) | (2.0) | |||||||||||||
| Total New BD Adjusted Revenue (2) | $ | 4,726 | $ | 4,264 | $ | 17 | 10.8 | 10.4 | ||||||||||
| Adjusted Total Revenues | $ | 5,509 | $ | 5,057 | $ | 23 | 8.9 | 8.5 | ||||||||||
| Less Inorganic revenue adjustment (3) | 278 | - | 2 | NM | NM | |||||||||||||
| Organic Revenue | $ | 5,231 | $ | 5,057 | $ | 21 | 3.4 | 3.0 | ||||||||||
| Less Life Sciences Segment Revenue | 784 | 793 | 7 | (1.1) | (2.0) | |||||||||||||
| Total New BD Organic Revenue (4) | $ | 4,448 | $ | 4,264 | $ | 15 | 4.3 | 4.0 | ||||||||||
| Connected Care Revenue | $ | 1,166 | $ | 840 | $ | 5 | 38.8 | 38.2 | ||||||||||
| Less Inorganic revenue adjustment (3) | 278 | - | 2 | NM | NM | |||||||||||||
| Connected Care Organic Revenue | $ | 888 | $ | 840 | $ | 3 | 5.7 | 5.3 |
NM denotes that the percentage change is not meaningful.
(1)Represents the recognition of accruals relating to the Italian government medical device pay back legislation, as well as another legal matter, all of which substantially relate to years prior to fiscal year 2024.
(2)Total New BD Adjusted Revenue is inclusive of Adjusted Total Revenues attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
(3)Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition divestiture. Acquisitions include Advanced Patient Monitoring in the Connected Care segment.
(4)Total New BD Organic Revenue is inclusive of Organic Revenue attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUE BY BUSINESS SEGMENTS AND UNITS
Three Months Ended March 31,
(Unaudited, $ in millions)
| United States | International | Total | |||||||||||||||||||||||||||||||||||||||||||||
| % Change | % Change | ||||||||||||||||||||||||||||||||||||||||||||||
| 2025 | 2024 | % Change | 2025 | 2024 | FX Impact | Reported | FXN | 2025 | 2024 | FX Impact | Reported | FXN | |||||||||||||||||||||||||||||||||||
| Medical Essentials (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Delivery Solutions | $ | 687 | $ | 662 | 3.7 | $ | 430 | $ | 445 | $ | (20) | (3.3) | 1.3 | $ | 1,117 | $ | 1,107 | $ | (20) | 0.9 | 2.8 | ||||||||||||||||||||||||||
| Specimen Management | 242 | 236 | 2.7 | 213 | 222 | (9) | (4.1) | 0.1 | 456 | 458 | (9) | (0.6) | 1.4 | ||||||||||||||||||||||||||||||||||
| Total | $ | 929 | $ | 898 | 3.5 | $ | 643 | $ | 667 | $ | (30) | (3.5) | 0.9 | $ | 1,573 | $ | 1,565 | $ | (30) | 0.5 | 2.4 | ||||||||||||||||||||||||||
| Connected Care (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Management Solutions | $ | 662 | $ | 609 | 8.6 | $ | 149 | $ | 162 | $ | (6) | (8.2) | (4.5) | $ | 811 | $ | 772 | $ | (6) | 5.1 | 5.9 | ||||||||||||||||||||||||||
| Advanced Patient Monitoring | 155 | - | NM | 102 | - | (4) | NM | NM | 257 | - | (4) | NM | NM | ||||||||||||||||||||||||||||||||||
| Total | $ | 817 | $ | 609 | 34.1 | $ | 251 | $ | 162 | $ | (10) | 54.6 | 60.7 | $ | 1,068 | $ | 772 | $ | (10) | 38.4 | 39.7 | ||||||||||||||||||||||||||
| BioPharma Systems (1)(2) | $ | 149 | $ | 157 | (5.1) | $ | 426 | $ | 413 | $ | (7) | 3.2 | 5.0 | $ | 575 | $ | 570 | $ | (7) | 0.9 | 2.2 | ||||||||||||||||||||||||||
| Interventional (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Peripheral Intervention | $ | 269 | $ | 264 | 1.9 | $ | 212 | $ | 225 | $ | (8) | (5.5) | (1.9) | $ | 481 | $ | 489 | $ | (8) | (1.5) | 0.1 | ||||||||||||||||||||||||||
| Urology and Critical Care | 323 | 347 | (6.8) | 77 | 78 | (3) | (1.3) | 2.6 | 400 | 424 | (3) | (5.8) | (5.1) | ||||||||||||||||||||||||||||||||||
| Surgery | 289 | 287 | 0.5 | 94 | 92 | (3) | 2.5 | 6.1 | 383 | 379 | (3) | 1.0 | 1.9 | ||||||||||||||||||||||||||||||||||
| Total | $ | 880 | $ | 898 | (1.9) | $ | 384 | $ | 395 | $ | (14) | (2.8) | 0.8 | $ | 1,264 | $ | 1,292 | $ | (14) | (2.2) | (1.1) | ||||||||||||||||||||||||||
| Life Sciences (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Diagnostic Solutions | $ | 189 | $ | 201 | (5.8) | $ | 250 | $ | 267 | $ | (9) | (6.3) | (2.8) | $ | 440 | $ | 468 | $ | (9) | (6.1) | (4.1) | ||||||||||||||||||||||||||
| Biosciences | 142 | 142 | 0.2 | 209 | 235 | (7) | (10.7) | (7.9) | 352 | 377 | (7) | (6.6) | (4.8) | ||||||||||||||||||||||||||||||||||
| Total | $ | 332 | $ | 343 | (3.3) | $ | 460 | $ | 502 | $ | (16) | (8.4) | (5.2) | $ | 792 | $ | 845 | $ | (16) | (6.3) | (4.4) | ||||||||||||||||||||||||||
| Total Revenues | $ | 3,108 | $ | 2,906 | 7.0 | $ | 2,164 | $ | 2,139 | $ | (78) | 1.2 | 4.8 | $ | 5,272 | $ | 5,045 | $ | (78) | 4.5 | 6.0 |
NM denotes that the percentage change is not meaningful.
(1)Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.
(2)The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
RECONCILIATION OF REPORTED REVENUE CHANGE TO NEW BD REVENUE CHANGE AND REPORTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE
Three Months Ended March 31,
(Unaudited, $ in millions)
| % Change | |||||||||||||||||||
| 2025 | 2024 | FX Impact | Reported | FXN | |||||||||||||||
| Total Revenues | $ | 5,272 | $ | 5,045 | $ | (78) | 4.5 | 6.0 | |||||||||||
| Less Life Sciences Segment Revenue | 792 | 845 | (16) | (6.3) | (4.4) | ||||||||||||||
| Total New BD Revenue (1) | $ | 4,480 | $ | 4,200 | $ | (61) | 6.7 | 8.1 | |||||||||||
| Total Revenues | $ | 5,272 | $ | 5,045 | $ | (78) | 4.5 | 6.0 | |||||||||||
| Less Inorganic revenue adjustment (2) | 257 | - | (4) | NM | NM | ||||||||||||||
| Organic Revenue | $ | 5,015 | $ | 5,045 | $ | (74) | (0.6) | 0.9 | |||||||||||
| Less Life Sciences Segment Revenue | 792 | 845 | (16) | (6.3) | (4.4) | ||||||||||||||
| Total New BD Organic Revenue (3) | $ | 4,223 | $ | 4,200 | $ | (57) | 0.6 | 1.9 | |||||||||||
| Connected Care Revenue | $ | 1,068 | $ | 772 | $ | (10) | 38.4 | 39.7 | |||||||||||
| Less Inorganic revenue adjustment (2) | 257 | - | (4) | NM | NM | ||||||||||||||
| Connected Care Organic Revenue | $ | 811 | $ | 772 | $ | (6) | 5.1 | 5.9 |
NM denotes that the percentage change is not meaningful.
(1)Total New BD Revenue is inclusive of Total Revenues attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
(2)Inorganic revenue adjustment is defined as the amount of incremental revenue attributable to acquisitions and the revenue decline attributable to divestitures during the first 12 months post-acquisition divestiture. Acquisitions include Advanced Patient Monitoring in the Connected Care segment.
(3)Total New BD Organic Revenue is inclusive of Organic Revenue attributable to the Medical Essentials segment, Connected Care segment, BioPharma Systems segment, and Interventional segment.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUE BY BUSINESS SEGMENTS AND UNITS
Three Months Ended December 31,
(Unaudited, $ in millions)
| United States | International | Total | |||||||||||||||||||||||||||||||||||||||||||||
| % Change | % Change | ||||||||||||||||||||||||||||||||||||||||||||||
| 2024 | 2023 | % Change | 2024 | 2023 | FX Impact | Reported | FXN | 2024 | 2023 | FX Impact | Reported | FXN | |||||||||||||||||||||||||||||||||||
| Medical Essentials (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Delivery Solutions | $ | 694 | $ | 639 | 8.6 | $ | 430 | $ | 413 | $ | 1 | 4.3 | 4.1 | $ | 1,124 | $ | 1,052 | $ | 1 | 6.9 | 6.8 | ||||||||||||||||||||||||||
| Specimen Management | 238 | 234 | 2.0 | 223 | 213 | - | 4.8 | 4.7 | 462 | 447 | - | 3.3 | 3.3 | ||||||||||||||||||||||||||||||||||
| Total | $ | 932 | $ | 873 | 6.8 | $ | 654 | $ | 626 | $ | 1 | 4.4 | 4.3 | $ | 1,586 | $ | 1,498 | $ | 1 | 5.8 | 5.8 | ||||||||||||||||||||||||||
| Connected Care (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Medication Management Solutions | $ | 659 | $ | 594 | 11.0 | $ | 142 | $ | 153 | $ | 2 | (6.9) | (8.2) | $ | 801 | $ | 747 | $ | 2 | 7.3 | 7.1 | ||||||||||||||||||||||||||
| Advanced Patient Monitoring | 159 | - | NM | 113 | - | 1 | NM | NM | 271 | - | 1 | NM | NM | ||||||||||||||||||||||||||||||||||
| Total | $ | 818 | $ | 594 | 37.7 | $ | 255 | $ | 153 | $ | 3 | 67.0 | 65.3 | $ | 1,073 | $ | 747 | $ | 3 | 43.7 | 43.3 | ||||||||||||||||||||||||||
| BioPharma Systems (1)(2) | $ | 104 | $ | 127 | (18.5) | $ | 314 | $ | 304 | $ | - | 3.2 | 3.2 | $ | 418 | $ | 431 | $ | - | (3.2) | (3.2) | ||||||||||||||||||||||||||
| Interventional (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Peripheral Intervention | $ | 253 | $ | 234 | 7.8 | $ | 220 | $ | 220 | $ | 1 | 0.2 | (0.4) | $ | 473 | $ | 454 | $ | 1 | 4.1 | 3.8 | ||||||||||||||||||||||||||
| Urology and Critical Care | 306 | 287 | 6.6 | 83 | 78 | 1 | 6.8 | 5.4 | 389 | 365 | 1 | 6.6 | 6.3 | ||||||||||||||||||||||||||||||||||
| Surgery | 303 | 280 | 8.0 | 92 | 88 | 1 | 4.1 | 2.9 | 395 | 369 | 1 | 7.0 | 6.8 | ||||||||||||||||||||||||||||||||||
| Total | $ | 861 | $ | 802 | 7.4 | $ | 396 | $ | 386 | $ | 4 | 2.4 | 1.5 | $ | 1,257 | $ | 1,188 | $ | 4 | 5.8 | 5.5 | ||||||||||||||||||||||||||
| Life Sciences (1) | |||||||||||||||||||||||||||||||||||||||||||||||
| Diagnostic Solutions | $ | 212 | $ | 210 | 1.0 | $ | 262 | $ | 256 | $ | 1 | 2.2 | 1.9 | $ | 474 | $ | 467 | $ | 1 | 1.7 | 1.5 | ||||||||||||||||||||||||||
| Biosciences | 153 | 143 | 6.6 | 208 | 232 | 1 | (10.1) | (10.7) | 361 | 375 | 1 | (3.7) | (4.1) | ||||||||||||||||||||||||||||||||||
| Total | $ | 365 | $ | 354 | 3.3 | $ | 470 | $ | 488 | $ | 2 | (3.6) | (4.1) | $ | 836 | $ | 842 | $ | 2 | (0.7) | (1.0) | ||||||||||||||||||||||||||
| Total Revenues | $ | 3,080 | $ | 2,749 | 12.0 | $ | 2,089 | $ | 1,957 | $ | 9 | 6.7 | 6.3 | $ | 5,168 | $ | 4,706 | $ | 9 | 9.8 | 9.6 |
NM denotes that the percentage change is not meaningful.
(1)Effective October 1, 2025, the Company reorganized its organizational units into five distinct, separately-managed segments, which are based on the nature of the Company's product and service offerings. Prior period amounts have been recast to reflect the reorganization.
(2)The BioPharma Systems segment is comprised of the Company's former Pharmaceutical Systems organizational unit.
BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
RECONCILIATION OF REPORTED REVENUE CHANGE TO NEW BD REVENUE CHANGE AND REPORTED REVENUE CHANGE TO ORGANIC REVENUE CHANGE TO NEW BD ORGANIC REVENUE CHANGE
Three Months Ended December 31,
(Unaudited, $ in millions)